Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Marketing Expenses Up 1.5% to US$91 Bil. in 2010: CSD Survey
August 8, 2011
- Taiho's TAS-102 Prolongs OS in mCRC: JSMO Annual Meeting
August 8, 2011
- Oncology Products to Contribute to Astellas' Business from 2018 Onward: President Hatanaka
August 8, 2011
- Avastin's Efficacy in Combination with FOLFIRI for Colon Cancer Confirmed in Domestic PII Study
August 8, 2011
- Shionogi to Enter Chinese Market by Acquiring Local Company
August 8, 2011
- BioWa Licenses Potelligent Technology to arGEN-X
August 8, 2011
- Medipal, JCR Pharm. Announce Tie-up; Medipal to Invest in Drug Development
August 8, 2011
- Toyama Chemical to Construct New Pharmacology Research Lab
August 8, 2011
- RaQualia Licenses 5-HT4 Partial Agonist to CJ CheilJedang in South Korea
August 8, 2011
- Fujifilm, DRL Announce Plans to Establish Generic Drugs JV in Japan
August 8, 2011
- Astellas Transfers Investigational Anti-arrhythmic Agent to Merck Subsidiary
August 8, 2011
- Revision Proposed to 70% Rule for Pricing of New Generics
August 8, 2011
- Teijin Pharma's Gout Agent Febuxostat Launched in South Korea
August 8, 2011
- Korosho Orders 10-Day Suspension of Operations for Kobayashi Medical
August 8, 2011
- M3 to Promote Clinical Study Support Business by Acquiring SMO
August 8, 2011
- Roche to File for mBC Treatment Pertuzumab in Japan in 2012
August 8, 2011
- Korosho to Publish JAMS's Opinions on Switch OTC Drug Candidates Sometime in August
August 8, 2011
- Chuikyo to Assess Impact of “Premium for Development of New Drugs”
August 8, 2011
- Millennium Submits sNDA for Velcade in US
August 8, 2011
- Axitinib to Be Used in 3rd-line Therapy for RCC: Kantar Health
August 8, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…